Business Context and Reporting Period
This Form 8-K Current Report was filed by Pieris Pharmaceuticals, Inc. (PIRS) on April 24, 2021. The filing discloses the entry into a Material Definitive Agreement regarding the licensing of a preclinical immuno-oncology asset.
Key Financial Metrics and Transaction Details
The filing details a specific transaction rather than periodic financial performance metrics such as revenue, profit, or cash flow for a reporting period.
- Upfront Payment: $10 million received from Boston Pharmaceuticals.
- Potential Milestone Payments: Up to $352.5 million contingent on development, regulatory, and sales milestones.
- Royalties: Tiered royalties up to low double-digits on future sales of the licensed product.
- Additional Consideration: A percentage of proceeds from any sublicense or change of control of Boston Pharmaceuticals.
Material Changes and Agreement Terms
The primary material change is the execution of an Exclusive Product License Agreement with BP Asset XII, Inc. (Boston Pharmaceuticals) for PRS-342, a 4-1BB/GPC3 preclinical immuno-oncology Anticalin-antibody bispecific fusion protein.
- Licensing Scope: Boston Pharmaceuticals received exclusive worldwide rights to PRS-342.
- Termination Rights: Boston Pharmaceuticals may terminate for convenience after 9 months (60 days' notice) or 120 days' notice for approved programs. Pieris retains full rights to continue any terminated program.
- Manufacturing: Pieris will contribute an undisclosed amount toward manufacturing activities.
Outlook, Risks, and Contingencies
The agreement is contingent upon future development and regulatory success to unlock milestone payments. Risks include the potential for Boston Pharmaceuticals to terminate the agreement for convenience, which would halt future milestone payments but return rights to Pieris. The filing notes that the full agreement text will be filed as an exhibit to the Form 10-Q for the quarter ending June 30, 2021.
Investor Verification Checklist
- Verify the receipt of the $10 million upfront payment in subsequent cash flow statements.
- Review the full text of the Exclusive Product License Agreement when filed as an exhibit to the Q2 2021 Form 10-Q for specific milestone definitions.
- Monitor the development status of PRS-342 to assess the likelihood of achieving the $352.5 million in potential milestones.
- Confirm the specific amount Pieris is contributing toward manufacturing activities, as this was undisclosed in the 8-K.